Transforming Growth Factor-Beta and Oxidative Stress Interplay: Implications in Tumorigenesis and Cancer Progression

Abstract

Transforming growth factor-beta (TGF-β) and oxidative stress/Reactive Oxygen Species (ROS) both have pivotal roles in health and disease. In this review we are analyzing the interplay between TGF-β and ROS in tumorigenesis and cancer progression. They have contradictory roles in cancer progression since both can have antitumor effects, through the induction of cell death, senescence and cell cycle arrest, and protumor effects by contributing to cancer cell spreading, proliferation, survival, and metastasis. TGF-β can control ROS production directly or by downregulating antioxidative systems. Meanwhile, ROS can influence TGF-β signaling and increase its expression as well as its activation from the latent complex. This way, both are building a strong interplay which can be taken as an advantage by cancer cells in order to increment their malignancy. In addition, both TGF-β and ROS are able to induce cell senescence, which in one way protects damaged cells from neoplastic transformation but also may collaborate in cancer progression. The mutual collaboration of TGF-β and ROS in tumorigenesis is highly complex, and, due to their differential roles in tumor progression, careful consideration should be taken when thinking of combinatorial targeting in cancer therapies.

myo-Inositol Oxygenase Overexpression Accentuates Generation of Reactive Oxygen Species and Exacerbates Cellular Injury following High Glucose Ambience

“…Indeed, an intricate interplay between TGF-␤1 and ROS has been reported in various studies (reviewed in Ref. 59). Even in the kidney, increased caspase-3 activity, apoptosis, and ROS are seen in the setting of experimental chronic renal scarring or fibrosis (60).…”

Oxidative stress in cancer and fibrosis: Opportunity for therapeutic intervention with antioxidant compounds, enzymes, and nanoparticles

“…Similar to fibrosis, the cross-talk between ROS and TGF-β signaling in cancer has been well-documented and comprehensively reviewed [62], [63]. TGF-β1 is one of the most potent cytokines known to contribute to immunosuppression of immune cells and promoting angiogenesis and EMT in cancer cells [64].…”

Doxorubicin cardiotoxicity and target cells: a broader perspective

“…The latter has been recognized as a strong stimulator of pathological collagen production as well as activator of transforming growth factor-β (TGF-β), a cytokine that has been associated to fibro-inflammatory signaling [70][71][72]. In our model, DOX determined significant increases of TGF-β and phospho-SMAD3 along with an increment of collagen deposition, and enhanced phenotypic transformation of fibroblasts to myofibroblasts, cells that express contractile proteins and secrete pro-fibrotic factors [73].…”